Theseus Pharmaceuticals (THRX) 10-Q2023 Q1 Quarterly report

Filed: 11 May 23, 7:12am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: acquisition, acute, appointment, Assuming, ATM, attempt, beginning, broader, chronic, closure, CML, CMO, cohort, confidence, coupled, create, created, diagnosed, difficulty, employ, evidence, face, FDIC, hour, instability, institution, jointly, lesser, leukemia, lymphoblastic, macroeconomic, mitigate, monotherapy, myeloid, newly, open, percent, Ph, pharmacokinetic, Philadelphia, PK, political, population, preceding, preliminary, primary, reached, receivership, recession, recognition, released, sarcoma, Secondary, shelf, shown, Signature, Silicon, stomach, swept, thereof, tract, Treasury, unallocated, unrest, Valley, volatility, wage, worldwide

Removed: accessible, accounted, adjusted, allocated, allocation, alter, announced, arrangement, asset, authorize, bifurcated, borrowing, carried, category, certificate, commenced, conducting, consideration, consistent, decrease, derived, determinable, direct, directly, discount, dosing, effected, entered, epidemic, estate, evolve, evolving, exit, expiration, extend, feet, fixed, fractional, framework, identical, iii, immaterial, implemented, implicit, inclusive, incorporation, incremental, indirectly, intent, investee, iv, July, leased, length, lessor, letter, lieu, local, located, maintenance, measurement, measuring, nonrecurring, observable, office, orderly, outbreak, participate, pertaining, point, premium, proportionate, proportionately, qualitative, quantitative, quoted, readily, real, receiving, reclassifying, redeemable, reduced, reduction, rentable, representing, restated, resulted, retroactively, reverse, revision, ROU, select, simplified, situation, space, split, spread, square, sum, supported, temporary, tranche, transaction, transfer, transferred, ultimate, unobservable, utilizing, variable, withheld

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

THRX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Theseus Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.


Date: May 11, 2023	By:	/s/ Timothy P. Clackson, Ph.D.
		Name: Timothy P. Clackson, Ph.D.
		Title: President and Chief Executive Officer (Principal Executive Officer)